EXHIBIT 99.1

 

 

FOR IMMEDIATE RELEASE

CONTACTS:

David Green

CEO

dgreen@hartregen.com

 

Tom McNaughton

CFO

tmcnaughton@hartregen.com

 

Tel: 774-233-7321

Fax: 774-233-7302

 

Harvard Apparatus Regenerative Technology Reports Operating Results for the Fourth Quarter and Year Ended December 31, 2014

 

-Conference Call To Be Held at 11:00 AM ET Today-

 

Holliston, MA, March 19, 2015

- Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, reports unaudited financial results for the three months and year ended December 31, 2014.

 

David Green, President and CEO of Harvard Apparatus Regenerative Technology, commented, “ During the full year of 2014, and more recently, we made significant progress on critical aspects of making regenerated organs for transplant a reality for patients. Highlights include:

 

·The 5th adult patient was transplanted with a HART-Trachea.
·Average survival among the 5 patients has been 22 months which is a significant improvement over the prognosis at the time of transplant which was typically just a few months. Of the three patients who have died, none of them died because of a failure of our scaffold. Two of the patients are still alive. One is at approximately 9 months and one at approximately two and a half years from transplant.
·We received orphan status in the U.S. This will give us 7 years of exclusivity in the U.S. from the date of launch of the HART-Trachea.
·We have moved away from Russian clinical studies towards US clinical studies, in particular with our collaboration agreement with Mayo Clinic, one of the world’s leading hospitals.

 


The following information was filed by Biostage, Inc. (BSTG) on Thursday, March 19, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Biostage, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biostage, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

FREE Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue for FREE

Log in with your credentials

or    

Forgot your details?

Create Account